Previous 10 |
Thinly traded micro cap Bicycle Therapeutics (NASDAQ: BCYC ) is up 10% premarket on light volume on the heels of encouraging data from an open-label Phase 1 clinical trial evaluating a single intravitreal injection of THR-149, a Bicycle-based plasma kallikrein inhibitor, in pat...
Phase I results provide additional clinical activity data for Bicycles Bicycle Therapeutics , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced the successful completion of Oxurion...
Gainers: Axovant Gene Therapies (NASDAQ: AXGT ) +40% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +24% . India Globalization Capital (NYSEMKT: IGC ) +17% . Pintec Technology (NASDAQ: PT ) +14% . ObsEva SA (NASDAQ: OBSV ) +12% . Overstock.com (NASDAQ: OSTK ) +12% . Fuwei Films (NASDAQ...
News, Short Squeeze, Breakout and More Instantly...
Bicycle Therapeutics plc Company Name:
BCYC Stock Symbol:
NYSE Market:
Bicycle Therapeutics plc Website:
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ® ) technology, today announced the acceptance of four abstracts for poster presentation at the European So...
2024-06-10 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Emerging clinical pharmacokinetic and safety profiles of Bicycle Toxin Conjugates ® demonstrate differentiation compared to antibody drug conjugates Trial-in-progress poster outlines registrational Phase 2/3 Duravelo-2 trial of BT8009, a Nectin-4 targeted Bicycle Toxin Conjugate,...